Natalizumab antibody | AbD21375_hIgG1




Human anti Natalizumab:HRP
Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
Human anti Natalizumab
Anti-natalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical assays for natalizumab and biosimilars. It is recommended as detection antibody in a PK bridging ELISA and as a reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
- Clone
- AbD21375_hIgG1
- Isotype
- IgG1
Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|
HCA249P | E | 0.1 mg |
![]() |
|
HCA249 | E | 0.1 mg |
![]() |
|
HCA249G | E | 1 mg |
![]() |
Clone AbD21375_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay. Additionally it can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody is recommended as the detection antibody, paired with Anti-Natalizumab Antibody clone AbD21375 (HCA248) in monovalent Fab format as the capture antibody.
Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. It is directed against alpha-4 integrin (CD49d), and binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes, except neutrophils. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier.
View a summary of all anti-natalizumab antibodies
Product Details
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Natalizumab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD = 2.1 nM by real time, label free molecular interaction analysis on immobilized natalizumab.
- Approx. Protein Concentrations
- IgG concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 0.1 mgAntibody concentration 0.5 mg/mlPack Size: 1 mgAntibody concentration 1.0 mg/ml
Storage Information
- Storage
- Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. - Storage
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Tysabri® is a registered trademark Biogen Idec and Elan.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Tysabri® is a registered trademark Biogen Idec and Elan.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Natalizumab antibody
Application Name | Verified | Min Dilution | Max Dilution |
---|---|---|---|
ELISA | |||
ELISA |
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug - ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA
Useful Reagents Available
Description | Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|---|
Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
Human anti Natalizumab | HCA248 | E | 0.1 mg |
![]() |
|
Human anti Natalizumab | HCA250 | E | 0.1 mg |
![]() |
|
Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
Human anti Natalizumab | HCA248 | E | 0.1 mg |
![]() |
|
Human anti Natalizumab | HCA250 | E | 0.1 mg |
![]() |
|
LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | ||
Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C* E | 0.2 mg |
![]() |
Product Specific References
References for Natalizumab antibody
-
Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
US Patent US20170315118A1
Fluorescent Spectraviewer
Watch the Tool Tutorial Video ▸
How to Use the Spectraviewer?
Watch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra